Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 9044.084 | 1.1582 | 1.7212 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 9044.084 | 1.2118 | 1.9917 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 9044.084 | 1.2984 | 2.4581 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 9044.084 | 1.1645 | 1.7522 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 9044.084 | 1.1665 | 1.7622 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 9044.084 | 1.1924 | 1.8924 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 9044.084 | 1.0347 | 1.1483 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 9044.084 | 1.1630 | 1.7450 | 0.4769 | |
| SUM1315MO2 | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 9044.084 | 1.1682 | 1.7705 | 0.4769 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7530.085 | 0.9594 | 0.9615 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7530.085 | 0.9978 | 0.9980 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7530.085 | 0.9515 | 0.9540 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7530.085 | 1.1040 | 1.0949 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7530.085 | 1.0974 | 1.0890 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7530.085 | 1.0405 | 1.0375 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7530.085 | 0.5712 | 0.5384 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 66.7 | uM | 7530.085 | 0.2136 | -0.0297 | 2.1343 | |
| SUM149PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 333 | uM | 7530.085 | 0.0068 | -0.8065 | 2.1343 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.000853 | uM | 7531.085 | 0.9995 | 0.9997 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00427 | uM | 7531.085 | 1.1422 | 1.0770 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0213 | uM | 7531.085 | 1.0637 | 1.0354 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.107 | uM | 7531.085 | 1.2083 | 1.1105 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.533 | uM | 7531.085 | 1.2453 | 1.1286 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 2.67 | uM | 7531.085 | 0.9264 | 0.9570 | 3.5188 | |
| SUM159PT | TNBC | Basal B | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 13.3 | uM | 7531.085 | 0.7122 | 0.8161 | 3.5188 |